Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-16-019683
Filing Date
2016-05-19
Accepted
2016-05-19 06:05:24
Documents
60
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q agle-10q_20160331.htm 10-Q 1355497
2 EX-31.1 agle-ex311_23.htm EX-31.1 14581
3 EX-31.2 agle-ex312_22.htm EX-31.2 14174
4 EX-32.1 agle-ex321_21.htm EX-32.1 6827
5 EX-32.2 agle-ex322_20.htm EX-32.2 6842
  Complete submission text file 0001564590-16-019683.txt   4583932

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT agle-20160331.xml EX-101.INS 807774
7 XBRL TAXONOMY EXTENSION SCHEMA agle-20160331.xsd EX-101.SCH 42294
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE agle-20160331_cal.xml EX-101.CAL 33710
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE agle-20160331_def.xml EX-101.DEF 144746
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20160331_lab.xml EX-101.LAB 298667
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20160331_pre.xml EX-101.PRE 238414
Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37722 | Film No.: 161661864
SIC: 2834 Pharmaceutical Preparations